166 related articles for article (PubMed ID: 15316323)
21. Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens.
Browne TJ; Hirsch MS; Brodsky G; Welch WR; Loda MF; Rubin MA
Hum Pathol; 2004 Dec; 35(12):1462-8. PubMed ID: 15619204
[TBL] [Abstract][Full Text] [Related]
22. Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer.
Nassar A; Amin MB; Sexton DG; Cohen C
Appl Immunohistochem Mol Morphol; 2005 Sep; 13(3):252-5. PubMed ID: 16082251
[TBL] [Abstract][Full Text] [Related]
23. Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia.
Aron M; Luthringer DJ; McKenney JK; Hansel DE; Westfall DE; Parakh R; Mohanty SK; Balzer B; Amin MB
Am J Surg Pathol; 2013 Dec; 37(12):1815-23. PubMed ID: 24225842
[TBL] [Abstract][Full Text] [Related]
24. Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia.
Wu CL; Yang XJ; Tretiakova M; Patton KT; Halpern EF; Woda BA; Young RH; Jiang Z
Hum Pathol; 2004 Aug; 35(8):1008-13. PubMed ID: 15297968
[TBL] [Abstract][Full Text] [Related]
25. Expression of alpha-methylacyl-CoA racemase (P504S) in sebaceous neoplasms.
Halsey MA; Calder KB; Mathew R; Schlauder S; Morgan MB
J Cutan Pathol; 2010 Apr; 37(4):446-51. PubMed ID: 19638170
[TBL] [Abstract][Full Text] [Related]
26. Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma.
Olgac S; Hutchinson B; Tickoo SK; Reuter VE
Mod Pathol; 2006 Feb; 19(2):218-24. PubMed ID: 16424894
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
Herawi M; Epstein JI
Am J Surg Pathol; 2007 Jun; 31(6):889-94. PubMed ID: 17527076
[TBL] [Abstract][Full Text] [Related]
28. Differential expression of alpha-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance.
Lin A; Weiser MR; Klimstra DS; Paty PB; Tang LH; Al-Ahmadie H; Hoo Park S; Guillem JG; Temple L; Wong WD; Gerald WL; Shia J
Hum Pathol; 2007 Jun; 38(6):850-6. PubMed ID: 17442371
[TBL] [Abstract][Full Text] [Related]
29. AMACR is associated with advanced pathologic risk factors in sporadic colorectal adenomas.
Lakis S; Papamitsou T; Panagiotopoulou C; Kotakidou R; Kotoula V
World J Gastroenterol; 2010 May; 16(20):2476-83. PubMed ID: 20503447
[TBL] [Abstract][Full Text] [Related]
30. Nephrogenic adenoma of the urinary tract: a review.
Alexiev BA; LeVea CM
Int J Surg Pathol; 2012 Apr; 20(2):123-31. PubMed ID: 22415059
[TBL] [Abstract][Full Text] [Related]
31. Nephrogenic adenoma of the urinary tract: A 6-year single center experience.
Turcan D; Acikalin MF; Yilmaz E; Canaz F; Arik D
Pathol Res Pract; 2017 Jul; 213(7):831-835. PubMed ID: 28554748
[TBL] [Abstract][Full Text] [Related]
32. Increased expression of α-methylacyl-coenzyme A racemase (AMACR; p504s) and p16 in distal hyperplastic polyps.
Dayi N; Baba HA; Schmid KW; Schmitz KJ
Diagn Pathol; 2013 Oct; 8():178. PubMed ID: 24152881
[TBL] [Abstract][Full Text] [Related]
33. Heterogeneous expression of alpha-methylacyl-CoA racemase in prostatic cancer correlates with Gleason score.
Murphy AJ; Hughes CA; Lannigan G; Sheils O; O'Leary J; Loftus B
Histopathology; 2007 Jan; 50(2):243-51. PubMed ID: 17222253
[TBL] [Abstract][Full Text] [Related]
34. PAX2: a reliable marker for nephrogenic adenoma.
Tong GX; Melamed J; Mansukhani M; Memeo L; Hernandez O; Deng FM; Chiriboga L; Waisman J
Mod Pathol; 2006 Mar; 19(3):356-63. PubMed ID: 16400326
[TBL] [Abstract][Full Text] [Related]
35. Clear cell adenocarcinoma of urinary bladder and urethra: another urinary tract lesion immunoreactive for P504S.
Sun K; Huan Y; Unger PD
Arch Pathol Lab Med; 2008 Sep; 132(9):1417-22. PubMed ID: 18788852
[TBL] [Abstract][Full Text] [Related]
36. Is atypical adenomatous hyperplasia of the prostate a precursor lesion?
Zhang C; Montironi R; MacLennan GT; Lopez-Beltran A; Li Y; Tan PH; Wang M; Zhang S; Iczkowski KA; Cheng L
Prostate; 2011 Dec; 71(16):1746-51. PubMed ID: 21480308
[TBL] [Abstract][Full Text] [Related]
37. Nephrogenic Adenoma of the Prostatic Urethra Mimicking Prostatic and Bladder Carcinomas.
Beeter MC; Fazili T; Yeh YA
Cureus; 2023 Mar; 15(3):e35998. PubMed ID: 37041930
[TBL] [Abstract][Full Text] [Related]
38. Utility of immunohistochemistry for alpha-methylacyl-CoA racemase in distinguishing atrophic prostate cancer from benign atrophy.
Farinola MA; Epstein JI
Hum Pathol; 2004 Oct; 35(10):1272-8. PubMed ID: 15492996
[TBL] [Abstract][Full Text] [Related]
39. Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis?
Tong GX; Weeden EM; Hamele-Bena D; Huan Y; Unger P; Memeo L; O'Toole K
Am J Surg Pathol; 2008 Sep; 32(9):1380-7. PubMed ID: 18670350
[TBL] [Abstract][Full Text] [Related]
40. Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions.
Zhou M; Chinnaiyan AM; Kleer CG; Lucas PC; Rubin MA
Am J Surg Pathol; 2002 Jul; 26(7):926-31. PubMed ID: 12131161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
